O	0	6	Effect	Effect	NN	B-NP
O	7	9	of	of	IN	B-PP
O	10	11	a	a	DT	B-NP
O	12	20	mutation	mutation	NN	I-NP
O	21	23	in	in	IN	B-PP
O	24	27	the	the	DT	B-NP
O	28	37	anticodon	anticodon	NN	I-NP
O	38	40	of	of	IN	B-PP
O	41	46	human	human	JJ	B-NP
B-Cellular_component	47	60	mitochondrial	mitochondrial	JJ	I-NP
O	61	68	tRNAPro	tRNAPro	NN	I-NP
O	69	71	on	on	IN	B-PP
O	72	75	its	its	PRP$	B-NP
O	76	80	post	post	AFX	I-NP
O	80	81	-	-	HYPH	I-NP
O	81	96	transcriptional	transcriptional	JJ	I-NP
O	97	109	modification	modification	NN	I-NP
O	110	117	pattern	pattern	NN	I-NP
O	117	118	.	.	.	O

O	119	127	Although	Although	IN	B-SBAR
O	128	131	the	the	DT	B-NP
O	132	136	gene	gene	NN	I-NP
O	137	146	sequences	sequence	NNS	I-NP
O	147	149	of	of	IN	B-PP
O	150	153	all	all	DT	B-NP
O	154	156	22	22	CD	I-NP
O	157	162	tRNAs	tRNA	NNS	I-NP
O	163	170	encoded	encode	VBN	B-VP
O	171	173	in	in	IN	B-PP
O	174	177	the	the	DT	B-NP
O	178	183	human	human	JJ	I-NP
B-Cellular_component	184	197	mitochondrial	mitochondrial	JJ	I-NP
I-Cellular_component	198	204	genome	genome	NN	I-NP
O	205	208	are	be	VBP	B-VP
O	209	214	known	know	VBN	I-VP
O	214	215	,	,	,	O
O	216	222	little	little	JJ	B-NP
O	223	234	information	information	NN	I-NP
O	235	241	exists	exist	VBZ	B-VP
O	242	247	about	about	IN	B-PP
O	248	253	their	their	PRP$	B-NP
O	254	263	sequences	sequence	NNS	I-NP
O	264	266	at	at	IN	B-PP
O	267	270	the	the	DT	B-NP
O	271	274	RNA	RNA	NN	I-NP
O	275	280	level	level	NN	I-NP
O	280	281	.	.	.	O

O	282	286	This	This	DT	B-NP
O	287	294	becomes	become	VBZ	B-VP
O	295	296	a	a	DT	B-NP
O	297	304	crucial	crucial	JJ	I-NP
O	305	315	limitation	limitation	NN	I-NP
O	316	320	when	when	WRB	B-ADVP
O	321	330	searching	search	VBG	B-VP
O	331	334	for	for	IN	B-PP
O	335	336	a	a	DT	B-NP
O	337	346	molecular	molecular	JJ	I-NP
O	347	360	understanding	understanding	NN	I-NP
O	361	363	of	of	IN	B-PP
O	364	367	the	the	DT	B-NP
O	368	375	growing	grow	VBG	I-NP
O	376	382	number	number	NN	I-NP
O	383	385	of	of	IN	B-PP
O	386	396	maternally	maternally	RB	B-NP
O	397	406	inherited	inherit	VBN	I-NP
O	407	412	human	human	JJ	I-NP
O	413	421	diseases	disease	NNS	I-NP
O	422	432	correlated	correlate	VBD	B-VP
O	433	437	with	with	IN	B-PP
O	438	443	point	point	NN	B-NP
O	444	453	mutations	mutation	NNS	I-NP
O	454	456	in	in	IN	B-PP
O	457	461	tRNA	tRNA	NN	B-NP
O	462	467	genes	gene	NNS	I-NP
O	467	468	.	.	.	O

O	469	473	Here	Here	RB	B-ADVP
O	474	476	we	we	PRP	B-NP
O	477	485	describe	describe	VBP	B-VP
O	486	489	the	the	DT	B-NP
O	490	498	sequence	sequence	NN	I-NP
O	499	501	of	of	IN	B-PP
O	502	507	human	human	JJ	B-NP
O	508	510	mt	mt	NN	I-NP
O	510	511	-	-	HYPH	O
O	511	526	tRNAPropurified	tRNAPropurifie	VBN	B-VP
O	527	531	from	from	IN	B-PP
B-Organ	532	540	placenta	placenta	NN	B-NP
O	540	541	.	.	.	O

O	542	544	It	It	PRP	B-NP
O	545	550	shows	show	VBZ	B-VP
O	551	558	absence	absence	NN	B-NP
O	559	561	of	of	IN	B-PP
O	562	569	editing	edit	VBG	B-VP
O	570	576	events	event	NNS	B-NP
O	577	579	in	in	IN	B-PP
O	580	584	this	this	DT	B-NP
O	585	589	tRNA	tRNA	NN	I-NP
O	590	593	and	and	CC	O
O	594	604	highlights	highlight	VBZ	B-VP
O	605	608	the	the	DT	B-NP
O	609	617	presence	presence	NN	I-NP
O	618	620	of	of	IN	B-PP
O	621	626	eight	eight	CD	B-NP
O	627	631	post	post	AFX	I-NP
O	631	632	-	-	HYPH	I-NP
O	632	647	transcriptional	transcriptional	JJ	I-NP
O	648	661	modifications	modification	NNS	I-NP
O	661	662	.	.	.	O

O	663	668	These	These	DT	B-NP
O	669	676	include	include	VBP	B-VP
O	677	680	T54	T54	NN	B-NP
O	680	681	,	,	,	O
O	682	687	never	never	RB	B-VP
O	688	693	found	find	VBN	I-VP
O	694	696	so	so	RB	B-ADVP
O	697	700	far	far	RB	I-ADVP
O	701	703	in	in	IN	B-PP
O	704	706	an	an	DT	B-NP
O	707	713	animal	animal	NN	I-NP
O	714	716	mt	mt	NN	I-NP
O	716	717	-	-	HYPH	B-NP
O	717	721	tRNA	tRNA	NN	I-NP
O	721	722	,	,	,	O
O	723	726	and	and	CC	O
O	727	732	m1G37	m1G37	NN	B-NP
O	732	733	,	,	,	O
O	734	735	a	a	DT	B-NP
O	736	748	modification	modification	NN	I-NP
O	749	754	known	know	VBN	B-VP
O	755	757	to	to	TO	I-VP
O	758	762	have	have	VB	I-VP
O	763	774	fundamental	fundamental	JJ	B-NP
O	775	785	functional	functional	JJ	I-NP
O	786	796	properties	property	NNS	I-NP
O	797	799	in	in	IN	B-PP
O	800	801	a	a	DT	B-NP
O	802	808	number	number	NN	I-NP
O	809	811	of	of	IN	B-PP
O	812	821	canonical	canonical	JJ	B-NP
O	822	827	tRNAs	tRNA	NNS	I-NP
O	827	828	.	.	.	O

O	829	839	Occurrence	Occurrence	NN	B-NP
O	840	842	of	of	IN	B-PP
O	843	848	m1G37	m1G37	NN	B-NP
O	849	852	was	be	VBD	B-VP
O	853	860	further	further	RBR	I-VP
O	861	873	investigated	investigate	VBN	I-VP
O	874	876	in	in	IN	B-PP
O	877	879	an	an	DT	B-NP
O	880	888	analysis	analysis	NN	I-NP
O	889	891	of	of	IN	B-PP
O	892	895	the	the	DT	B-NP
O	896	905	substrate	substrate	NN	I-NP
O	906	916	properties	property	NNS	I-NP
O	917	919	of	of	IN	B-PP
O	920	922	in	in	FW	B-NP
O	923	928	vitro	vitro	FW	I-NP
O	929	940	transcripts	transcript	NNS	I-NP
O	941	943	of	of	IN	B-PP
O	944	949	human	human	JJ	B-NP
O	950	952	mt	mt	NN	I-NP
O	952	953	-	-	HYPH	O
O	953	967	tRNAProtowards	tRNAProtoward	NNS	B-NP
O	968	972	pure	pure	JJ	B-ADJP
O	973	984	Escherichia	Escherichia	FW	B-NP
O	985	989	coli	coli	FW	I-NP
O	990	1005	methylguanosine	methylguanosine	NN	I-NP
O	1006	1017	transferase	transferase	NN	I-NP
O	1017	1018	.	.	.	O

O	1019	1023	This	This	DT	B-NP
O	1024	1030	enzyme	enzyme	NN	I-NP
O	1031	1039	properly	properly	RB	B-ADVP
O	1040	1050	methylates	methylate	VBZ	B-VP
O	1051	1054	G37	G37	NN	B-NP
O	1055	1057	in	in	IN	B-PP
O	1058	1060	mt	mt	NN	B-NP
O	1060	1061	-	-	HYPH	B-NP
O	1061	1065	tRNA	tRNA	NN	I-NP
O	1066	1069	and	and	CC	O
O	1070	1072	is	be	VBZ	B-VP
O	1073	1082	sensitive	sensitive	JJ	B-ADJP
O	1083	1085	to	to	TO	B-PP
O	1086	1089	the	the	DT	B-NP
O	1090	1098	presence	presence	NN	I-NP
O	1099	1101	of	of	IN	B-PP
O	1102	1103	a	a	DT	B-NP
O	1104	1110	second	second	JJ	I-NP
O	1111	1112	G	G	NN	I-NP
O	1113	1115	at	at	IN	B-PP
O	1116	1124	position	position	NN	B-NP
O	1125	1127	36	36	CD	I-NP
O	1127	1128	,	,	,	O
O	1129	1140	neighboring	neighbor	VBG	B-VP
O	1141	1144	the	the	DT	B-NP
O	1145	1151	target	target	NN	I-NP
O	1152	1162	nucleotide	nucleotide	NN	I-NP
O	1163	1166	for	for	IN	B-PP
O	1167	1178	methylation	methylation	NN	B-NP
O	1178	1179	.	.	.	O

O	1180	1185	Since	Since	IN	B-PP
O	1186	1194	mutation	mutation	NN	B-NP
O	1195	1197	of	of	IN	B-PP
O	1198	1200	nt	nt	NN	B-NP
O	1201	1203	36	36	CD	I-NP
O	1204	1207	was	be	VBD	B-VP
O	1208	1213	shown	show	VBN	I-VP
O	1214	1216	to	to	TO	I-VP
O	1217	1219	be	be	VB	I-VP
O	1220	1230	correlated	correlate	VBN	I-VP
O	1231	1235	with	with	IN	B-PP
O	1236	1244	myopathy	myopathy	NN	B-NP
O	1244	1245	,	,	,	O
O	1246	1249	the	the	DT	B-NP
O	1250	1259	potential	potential	JJ	I-NP
O	1260	1272	consequences	consequence	NNS	I-NP
O	1273	1275	of	of	IN	B-PP
O	1276	1279	non	non	AFX	B-NP
O	1279	1280	-	-	HYPH	I-NP
O	1280	1292	modification	modification	NN	I-NP
O	1293	1295	or	or	CC	B-PP
O	1296	1301	under	under	IN	B-PP
O	1301	1302	-	-	HYPH	B-NP
O	1302	1314	modification	modification	NN	I-NP
O	1315	1317	of	of	IN	B-PP
O	1318	1320	mt	mt	NN	B-NP
O	1320	1321	-	-	HYPH	B-NP
O	1321	1325	tRNA	tRNA	NN	I-NP
O	1326	1337	nucleotides	nucleotide	NNS	I-NP
O	1338	1340	in	in	IN	B-PP
O	1341	1351	expression	expression	NN	B-NP
O	1352	1354	of	of	IN	B-PP
O	1355	1358	the	the	DT	B-NP
O	1359	1369	particular	particular	JJ	I-NP
O	1370	1378	myopathy	myopathy	NN	I-NP
O	1379	1382	and	and	CC	B-PP
O	1383	1385	of	of	IN	B-PP
B-Cellular_component	1386	1399	mitochondrial	mitochondrial	JJ	B-NP
O	1400	1408	diseases	disease	NNS	I-NP
O	1409	1411	in	in	IN	B-PP
O	1412	1419	general	general	JJ	B-ADJP
O	1420	1423	are	be	VBP	B-VP
O	1424	1433	discussed	discuss	VBN	I-VP
O	1433	1434	.	.	.	O

